The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index; none of the 73 sources its claims cite is checked for support yet.
The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome
Open accessAbstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and debilitating condition characterized by symptoms such as bladder pain, frequent urination, and nocturia. Pain is typically perceived in the lower abdomen, pelvic floor, or urethra, causing significant discomfort and impacting quality of life. Due to the similarity of its symptoms with those of overactive bladder and acute bacterial cystitis, patients often face misdiagnosis and delayed appropriate treatment. Hunner’s (HIC) and non-Hunner’s IC (NHIC), each with distinct clinical presentations, urothelial dysfunction, chronic inflammation, and central sensitization and thus multimodal symptomatic treatment approaches, may be the most common pathogeneses of IC/BPS. Treatment of IC/BPS should involve identifying the different clinical phenotypes and underlying pathophysiology causing clinical symptoms and developing strategies tailored to the patient’s needs. This review discusses the roles of urine biomarkers, bladder inflammation, and glycosaminoglycans in the pathogenesis of IC/BPS. Various bladder treatment modalities are explored, including glycosaminoglycan replenishment, botulinum toxin A injection, platelet-rich plasma injection, low-energy shock waves, immunosuppression, and low-dose oral prednisolone. Pelvic floor muscle physiotherapy and bladder therapy combined with psychiatric consultation can help alleviate psychological stress and enhance the quality of life of patients with IC/BPS. Elucidating the pathological mechanisms and exploring diverse treatment options would help advance the care of individuals suffering from this challenging bladder condition.
Overview
CoChat Summary
TL;DR
IC/BPS is a chronic bladder pain syndrome with distinct Hunner (HIC) and non-Hunner (NHIC) phenotypes, each involving urothelial dysfunction, chronic inflammation, autoimmunity, viral infection, central sensitization, and pelvic/psychological factors. This narrative review synthesizes pathophysiologic mechanisms and proposes personalized multimodal therapy, including GAG replenishment, botulinum toxin A, platelet-rich plasma, low-energy shock waves, immunosuppression, and psychiatric/pelvic floor care.
Key findings
- HIC and NHIC are distinct disorders: HIC features Hunner lesions, severe bladder pain, contracted bladder, dense inflammation, and lymphoid follicle aggregation in 40% of cases; NHIC features glomerulation after hydrodistension and more associated functional somatic syndromes. EBV was detected in 87.5% of HIC bladder tissues versus 17.4% of NHIC patients with high-grade glomerulation, with latent and lytic infection suggesting persistent/reactivated EBV.
- Intravesical BoNT-A in a randomized placebo-controlled trial reduced pain at week 8 (−2.6 ± 2.8 vs. −0.9 ± 2.2, p = 0.021) and achieved success rates of 63% vs. 15% (p = 0.028); repeated injections were better than a single injection. PRP success improved from 45% after the first injection to 70% at the primary endpoint and remained 67.5% at 3 months after the fourth injection. LESW improved VAS ≥3 in 57.1% vs. 19.0% (LESWs vs. placebo; p = 0.011).
- Other reported responses: antihistamines, 63% (38/60); intravesical tacrolimus, 56% (13/24); low-dose prednisolone in HIC, 64.5% at 12 months with mean maintenance dose 3.0 mg. Cyclosporine showed greater reduction in urinary frequency and higher subjective response than pentosan polysulfate; certolizumab pegol improved bladder pain and frequency but was not superior to placebo until 18 weeks; adalimumab was not superior to placebo.
- The proposed multimodal algorithm is phenotype-driven: fulguration and antivirals for HIC; for NHIC, hydrodistension with BoNT-A every 6 months or suprapubic LESW plus GAG for significant pain/high-grade glomerulation; monthly PRP for four months plus GAG for frequency-predominant symptoms; pelvic floor physiotherapy and psychiatric consultation for pelvic pain and anxiety/depression.
Methods
- Narrative review; literature searched in PubMed, MEDLINE, and ScienceDirect from 1982 to April 2024 using keywords “interstitial cystitis” or “bladder pain syndrome” or “painful bladder syndrome” and “pathophysiology” or “bladder therapy,” limited to English-language full-text articles.
- Reviewed basic and clinical research on clinical characteristics, cystoscopic features, urine biomarkers, bladder inflammation, urothelial dysfunction, and novel bladder treatments; findings were synthesized narratively into a proposed multimodal treatment strategy. No systematic review, meta-analysis, or formal quality appraisal is described.
Limitations
- Stated in the paper: data from large randomized controlled studies are limited for GAG replenishment; clinical trials for BoNT-A, PRP, and LESW are few; a randomized comparative trial is lacking; there has been no comparison of safety and efficacy between novel and conventional treatments; and treatment duration and biomarkers for determining antiviral treatment duration have not been established.
- Evident from the text: this is a narrative review with a non-systematic search and no formal risk-of-bias assessment; many cited studies are small cohorts, single-center, or preliminary, and IC/BPS phenotypes are heterogeneous, limiting direct comparisons and generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 62 Not checked · 10 Own results and interpretations
In the paper
“A comprehensive search of the literature for randomized control trials of different intravesical therapies for IC/BPS showed statistically significant improvements in IC symptoms compared to the controls or placebos [99].”
§ The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome > 8. Multimodal Active Therapy Based on the Pathophysiology of IC/BPS
What the sources say
- Not checked yetcites [99] Park, J.J., Kim, K.T., Lee, E.J., Chun, J., Lee, S., Shim, S.R., and Kim, J.H. (2024). Current updates relating totreatment for interstitial cystitis/bladder pain syndrome: Systematic review and network meta-analysis. BMC Urol., 24. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Although BoNT-A, PRP, and LESWs have been shown to effectively reduce inflammation, improve urothelial regeneration, and improve IC symptoms in IC/BPS bladders, the relevant clinical trials are few.”
§ The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome > 8. Multimodal Active Therapy Based on the Pathophysiology of IC/BPS
What the sources say
- Not checked yetcites [98] Lin, 2020, New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome—Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave, Int. Neurourol. J. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“A randomized comparative trial is still lacking [98].”
§ The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome > 8. Multimodal Active Therapy Based on the Pathophysiology of IC/BPS
What the sources say
- Not checked yetcites [98] Lin, 2020, New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome—Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave, Int. Neurourol. J. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Since the pathophysiology of IC/BPS is multifactorial, an algorithm for treatment should be established in individual patients with IC/BPS.”
§ The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome > 8. Multimodal Active Therapy Based on the Pathophysiology of IC/BPS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“If acute inflammation is not resolved, chronic inflammatory cells may infiltrate into the suburothelium and the detrusor muscle, resulting in pan-cystitis and chronic scar formation [8].”
§ The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome > 2. The Pathophysiology of NHIC
What the sources say
- Not checked yetcites [8] Akiyama, 2020, Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives, Int. J. Urol. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
42 more claims
Create a free account to see all 73 claims and to verify the 73 references still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 22
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“56% (13/24) of the patients responded to tacrolimus installation”
§ The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome > 5. Autoimmune Reactions and Treatment for NHIC
Reported 56 · recomputed 54.166667
Citations
Cites
Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052719 · Cited by 1,694
van de Merwe, J. P., Nordling, J., Bouchelouche, P., Bouchelouche, K., Cervigni, M., Daha, L. K., Elneil, S., Fall, M., Hohlbrugger, G., Irwin, P., et al. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.019 · Cited by 952
Fibromyalgia and overlapping disorders: The unifying concept of central sensitivity syndromes
Yunus, M. B. (2007) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2006.12.009 · Cited by 780
AUA Guideline for the Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Hanno, P. M., Burks, D. A., Clemens, J. Q., Dmochowski, R. R., Erickson, D., FitzGerald, M. P., Forrest, J. B., Gordon, B., Gray, M., Mayer, R. D., et al. (2011) · Journal of Urology · doi:10.1016/j.juro.2011.03.064 · Cited by 687
Thangam, E. B., Jemima, E. A., Singh, H., Baig, M. S., Khan, M., Mathias, C. B., Church, M. K., & Saluja, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01873 · Cited by 534
Interstitial cystitis early diagnosis, pathology, and treatment
Messing, E. M., & Stamey, T. A. (1978) · Urology · doi:10.1016/0090-4295(78)90286-8 · Cited by 404
Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Clemens, J. Q., Erickson, D. R., Varela, N. P., & Lai, H. H. (2022) · Journal of Urology · doi:10.1097/ju.0000000000002756 · Cited by 362
The Mast Cell in Interstitial Cystitis: Role in Pathophysiology and Pathogenesis
Sant, G. R., Kempuraj, D., Marchand, J. E., & Theoharides, T. C. (2007) · Urology · doi:10.1016/j.urology.2006.08.1109 · Cited by 337
Parsons, C. L. (2007) · Urology · doi:10.1016/j.urology.2006.03.084 · Cited by 288
SANT, G. R., PROPERT, K. J., HANNO, P. M., BURKS, D., CULKIN, D., DIOKNO, A. C., HARDY, C., LANDIS, J. R., MAYER, R., MADIGAN, R., et al. (2003) · Journal of Urology · doi:10.1097/01.ju.0000083020.06212.3d · Cited by 281
Cited by
Global Consensus on Interstitial Cystitis/Bladder Pain Syndrome: An Update on Therapeutic Treatments
Buford, K., Peters, K. M., RIEDL, C. R., Mishra, N. N., Wyndaele, J., Lovász, S., Pinto, R. A., & Birder, L. A. (2025) · Neurourology and Urodynamics · doi:10.1002/nau.70106 · Cited by 19
Decoding Chronicity: Oxidative Stress and Inflammation as Systems Hubs
Formanowicz, D. (2025) · Biomedicines · doi:10.3390/biomedicines13122976 · Cited by 17
Anjum, İ., Nasir, A., Naseer, F., Ibrahim, A., Rehman, B., Bashir, F., & Ain, Q. T. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1483548 · Cited by 7
Yu, W., Jhang, J., Jiang, Y., & Kuo, H. (2026) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj-d-25-00028 · Cited by 4
Self-citationLong, X., Yu, B., Chen, M., Zhang, Q., Wang, Y., Huang, Y., Wu, J., Cen, P., Lan, H., Long, J., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178184 · Cited by 3
Metadata
- Authors
- Yu, W.-R., Jhang, J.-F., Jiang, Y.-H., & Kuo, H.-C.
- Affiliations
- Tzu Chi University (TW)
- Corresponding author
- Kuo, Hann-Chorng
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2024-09-10
- Volume
- 12
- Issue
- 9
- Pages
- 2051
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC11428245
- OpenAlex
- W4402430374
- Cited by
- 39
- References
- 99
- Citations by year
- 2026: 26 · 2025: 13
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Buddhist Tzu Chi Medical Foundation (TCMF-MP-110-03-01, TCMF-SP-112-01)
- Topics
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Health Sciences › Medicine › Urology › Urinary Tract Infections Management
- Keywords
- interstitial cystitis, urothelial dysfunction, chronic inflammation, central sensitization, urinary biomarkers, cystitis, glycosaminoglycans, botulinum toxin type A, platelet-rich plasma, low-energy shock wave therapy, immunosuppression, low-dose prednisolone, psychological stress, quality of life
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome. https://app.cochat.ai/papers/10.3390/biomedicines12092051
- The paper
- Yu, W.-R., Jhang, J.-F., Jiang, Y.-H., & Kuo, H.-C. (2024). The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome. Biomedicines. https://doi.org/10.3390/biomedicines12092051
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.